OMB Home White House Website

Agency:    Department of Defense--Military
Bureau:    Research, Development, Test, and Evaluation
Account:    Research, development, test, and evaluation, Army (21-2040)
Certifying Official:    Deputy Comptroller Program/Budget
Contact Information:    http://WWW.DOD.GOV   703-697-5131
Transportable Pathogen Reduction & Blood Safety System

1 recipient will receive $1,916,000. This is a continuing earmark.
Year Enacted: 2005
Description: The treatment of collected blood for transfusion in the battlefield has been identified by the Army Medical Research Acquisition Activity division of the Department of Defense as a priority for the armed forces. Naviagant Biotechnologies has been developing a process using riboflavin and light to reduce the concentrations of pathogens in collected blood components. To date, processes have been developed for treating platelets and plasma, and preliminary work has been undertaken for treating red blood cells. The purpose of this program is to evaluate the efficacy of the technology to inactivate parasites that could be a risk to the military and civilian blood supplies.
Beneficiary/Recipient Amount ($K) Program Type Address
Navigant Biotechnologies $1,916 For-Profit
Lakewood, CO
Source: Appropriations Report Language - Conference
Reference: 108-622
Location: Line 29, Page 256
Citation Excerpt: Transportable Pathogen Reduction & Blood Safety System

Last Modified: 16-Apr-2007

Federal Register    |   Jobs at OMB   |   FOIA   |  OMB Locator   |   |   Accessibility   |   Privacy Policy   |   Site Search   |   Help